Qualify For a Study or Trial

The biggest obstacle in getting a celiac drug to market is recruiting enough patients to participate in clinical trials. Your participation is critical.

Take charge of your celiac disease to make better treatments and, one day, a cure for celiac disease a reality. Gain a better understanding of your celiac disease and how to manage it and potentially benefit from new medications or therapies that can improve your symptoms and your quality of life. See if you may qualify for a study or trial today!

 

Current Studies & Trials

U.S. Multi-Site

SynCeD Study

This study is a phase 2a clinical trial testing the safety, tolerability, and efficacy of the investigational medication KAN-101. 

KAN-101 targets the immune cells that drive celiac disease and leaves the otherwise healthy components of the immune system intact. KAN-101 acts by re-educating T cells, or tolerizing them, so they do not respond to gluten antigens.  

This trial may be an option for you if you: 

  • Are 18-70 years old 
  • Have biopsy-confirmed celiac disease 
  • Currently follow a gluten-free diet 

Learn more at Anokion.com/SynCeD.

See If You Qualify

U.S. Multi-Site

ACeD-it Study

This study is a phase 1b/2 clinical trial testing the safety and tolerability of the investigational medication KAN-101. 

KAN-101 targets the immune cells that drive celiac disease and leaves the otherwise healthy components of the immune system intact. KAN-101 acts by re-educating T cells, or tolerizing them, so they do not respond to gluten antigens.  

Learn more at Anokion.com/ACeD-it.

 

Learn more

It is important for patients to fully understand the potential risks and benefits of participating in a study or clinical trial and to discuss their options with their healthcare provider before making a decision. However, for many celiac patients, participation in a study or clinical trial can be a valuable and rewarding experience.

If you have questions about participating in a clinical trial or study listed here, please contact us at [email protected] or 844-593-8169.